JP2016531853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531853A5 JP2016531853A5 JP2016516601A JP2016516601A JP2016531853A5 JP 2016531853 A5 JP2016531853 A5 JP 2016531853A5 JP 2016516601 A JP2016516601 A JP 2016516601A JP 2016516601 A JP2016516601 A JP 2016516601A JP 2016531853 A5 JP2016531853 A5 JP 2016531853A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- opls
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881857P | 2013-09-24 | 2013-09-24 | |
| US61/881,857 | 2013-09-24 | ||
| PCT/US2014/057234 WO2015048145A1 (en) | 2013-09-24 | 2014-09-24 | Compositions and methods for reducing antigen-specific immunogenicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531853A JP2016531853A (ja) | 2016-10-13 |
| JP2016531853A5 true JP2016531853A5 (OSRAM) | 2017-09-28 |
| JP6783652B2 JP6783652B2 (ja) | 2020-11-11 |
Family
ID=52744422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516601A Active JP6783652B2 (ja) | 2013-09-24 | 2014-09-24 | 抗原特異的免疫原性を低減するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160243220A1 (OSRAM) |
| EP (1) | EP3049103B1 (OSRAM) |
| JP (1) | JP6783652B2 (OSRAM) |
| CN (1) | CN105992591A (OSRAM) |
| ES (1) | ES2807550T3 (OSRAM) |
| WO (1) | WO2015048145A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240173389A1 (en) * | 2021-03-11 | 2024-05-30 | Lapix Therapeutics, Inc. | Compositions and Methods For Reducing Immune Intolerance |
| JP2024531259A (ja) | 2021-08-13 | 2024-08-29 | ラピックス セラピューティクス， インコーポレイテッド | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
| US20240351977A1 (en) * | 2021-08-13 | 2024-10-24 | Lapix Therapeutics, Inc. | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders |
| WO2024091902A1 (en) | 2022-10-25 | 2024-05-02 | Lapix Therapeutics, Inc. | Immune cell-engrafted non-human animals and non-human animal models |
| WO2024118602A1 (en) | 2022-11-29 | 2024-06-06 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110218B2 (en) | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
| US7625584B2 (en) | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
| US7351688B2 (en) | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
| US7875288B2 (en) | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Method for treating blood coagulation disorders |
| AU2007235463B2 (en) | 2006-03-30 | 2012-11-22 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| EP3058953A1 (en) * | 2009-07-07 | 2016-08-24 | The Research Foundation Of State University Of New York | Lipidic compositions for induction of immune tolerance |
-
2014
- 2014-09-24 JP JP2016516601A patent/JP6783652B2/ja active Active
- 2014-09-24 EP EP14848904.0A patent/EP3049103B1/en active Active
- 2014-09-24 ES ES14848904T patent/ES2807550T3/es active Active
- 2014-09-24 WO PCT/US2014/057234 patent/WO2015048145A1/en not_active Ceased
- 2014-09-24 US US15/024,071 patent/US20160243220A1/en not_active Abandoned
- 2014-09-24 CN CN201480062068.0A patent/CN105992591A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| JP2016513640A5 (OSRAM) | ||
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| JP2016531853A5 (OSRAM) | ||
| JP2016040284A5 (OSRAM) | ||
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| JP2018505882A5 (OSRAM) | ||
| JP2015520196A5 (OSRAM) | ||
| JP2015530399A5 (OSRAM) | ||
| MY189494A (en) | Methods of administering beta7 integrin antagonists | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| EP3054013A4 (en) | IMMUNOGENOUS FORMULATION WITH RECOMBINANT LIVE BCG FOR THE EXPRESSION OF ANTIGENES OF METAPNEUMOVIRUS (HMPV) IN A SUSPENSION MADE FROM A LYOPHILISATE WITHOUT THE NEED FOR A PHARMACEUTICAL USE AGENT | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| EA201391384A1 (ru) | Комплексы галлия, фармацевтические композиции и способы применения | |
| PH12015501459A1 (en) | Intranasal vaccination dosage regimen | |
| JP2010510218A5 (OSRAM) | ||
| RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
| JP2016514142A5 (OSRAM) |